Loading…

Anti-HIV Activity of Steric Block Oligonucleotides

:  The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2006-10, Vol.1082 (1), p.103-115
Main Authors: IVANOVA, GABRIELA, ARZUMANOV, ANDREY A., TURNER, JOHN J., REIGADAS, SANDRINE, TOULMÉ, JEAN-JACQUES, BROWN, DOUGLAS E., LEVER, ANDREW M.L., GAIT, MICHAEL J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3
cites cdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3
container_end_page 115
container_issue 1
container_start_page 103
container_title Annals of the New York Academy of Sciences
container_volume 1082
creator IVANOVA, GABRIELA
ARZUMANOV, ANDREY A.
TURNER, JOHN J.
REIGADAS, SANDRINE
TOULMÉ, JEAN-JACQUES
BROWN, DOUGLAS E.
LEVER, ANDREW M.L.
GAIT, MICHAEL J.
description :  The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.
doi_str_mv 10.1196/annals.1348.033
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20841346</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20833211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</originalsourceid><addsrcrecordid>eNqNkE1PwkAQhjdGI4ievZmevBV2u9v9OIJRQBES8SOeNu12alZKi92i8u8tluhRT5NMnvedzIPQKcFdQhTvRXkeZa5LKJNdTOkeahPBlM85DfZRG2MhfKkC2kJHzr1iTALJxCFqEUFYqChpo6CfV9YfjR-9vqnsu602XpF68wpKa7xBVpiFN8vsS5GvTQZFZRNwx-ggrY_CyW520MPV5f3FyJ_MhuOL_sQ3TGLqp4kRJCFGxISxKFUqDEMQmEMUSy45QJqEASEBCJpKJWNGlBFYyZDWexMD7aDzpndVFm9rcJVeWmcgy6IcirXTAZasfpz_B6S0PlWDvQY0ZeFcCalelXYZlRtNsN761I1PvfWpa5914mxXvY6XkPzyO4E1QBvgw2aw-atPT5_78-9av0lZV8HnTyoqF5oLKkL9NB1qenfNbwf4Rg_oF7rCj8c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20833211</pqid></control><display><type>article</type><title>Anti-HIV Activity of Steric Block Oligonucleotides</title><source>Wiley</source><creator>IVANOVA, GABRIELA ; ARZUMANOV, ANDREY A. ; TURNER, JOHN J. ; REIGADAS, SANDRINE ; TOULMÉ, JEAN-JACQUES ; BROWN, DOUGLAS E. ; LEVER, ANDREW M.L. ; GAIT, MICHAEL J.</creator><creatorcontrib>IVANOVA, GABRIELA ; ARZUMANOV, ANDREY A. ; TURNER, JOHN J. ; REIGADAS, SANDRINE ; TOULMÉ, JEAN-JACQUES ; BROWN, DOUGLAS E. ; LEVER, ANDREW M.L. ; GAIT, MICHAEL J.</creatorcontrib><description>:  The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1196/annals.1348.033</identifier><identifier>PMID: 17145931</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Anti-HIV Agents - administration &amp; dosage ; Anti-HIV Agents - pharmacology ; antiviral ; Cells, Cultured ; Drug Delivery Systems - methods ; HIV ; HIV - genetics ; HIV Long Terminal Repeat - drug effects ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; oligonucleotide ; Oligonucleotides - pharmacology ; Oligonucleotides - therapeutic use ; Peptide Nucleic Acids - therapeutic use ; RNA, Viral - drug effects ; steric block ; virucide</subject><ispartof>Annals of the New York Academy of Sciences, 2006-10, Vol.1082 (1), p.103-115</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</citedby><cites>FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17145931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>IVANOVA, GABRIELA</creatorcontrib><creatorcontrib>ARZUMANOV, ANDREY A.</creatorcontrib><creatorcontrib>TURNER, JOHN J.</creatorcontrib><creatorcontrib>REIGADAS, SANDRINE</creatorcontrib><creatorcontrib>TOULMÉ, JEAN-JACQUES</creatorcontrib><creatorcontrib>BROWN, DOUGLAS E.</creatorcontrib><creatorcontrib>LEVER, ANDREW M.L.</creatorcontrib><creatorcontrib>GAIT, MICHAEL J.</creatorcontrib><title>Anti-HIV Activity of Steric Block Oligonucleotides</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>:  The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.</description><subject>Anti-HIV Agents - administration &amp; dosage</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>antiviral</subject><subject>Cells, Cultured</subject><subject>Drug Delivery Systems - methods</subject><subject>HIV</subject><subject>HIV - genetics</subject><subject>HIV Long Terminal Repeat - drug effects</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>oligonucleotide</subject><subject>Oligonucleotides - pharmacology</subject><subject>Oligonucleotides - therapeutic use</subject><subject>Peptide Nucleic Acids - therapeutic use</subject><subject>RNA, Viral - drug effects</subject><subject>steric block</subject><subject>virucide</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNkE1PwkAQhjdGI4ievZmevBV2u9v9OIJRQBES8SOeNu12alZKi92i8u8tluhRT5NMnvedzIPQKcFdQhTvRXkeZa5LKJNdTOkeahPBlM85DfZRG2MhfKkC2kJHzr1iTALJxCFqEUFYqChpo6CfV9YfjR-9vqnsu602XpF68wpKa7xBVpiFN8vsS5GvTQZFZRNwx-ggrY_CyW520MPV5f3FyJ_MhuOL_sQ3TGLqp4kRJCFGxISxKFUqDEMQmEMUSy45QJqEASEBCJpKJWNGlBFYyZDWexMD7aDzpndVFm9rcJVeWmcgy6IcirXTAZasfpz_B6S0PlWDvQY0ZeFcCalelXYZlRtNsN761I1PvfWpa5914mxXvY6XkPzyO4E1QBvgw2aw-atPT5_78-9av0lZV8HnTyoqF5oLKkL9NB1qenfNbwf4Rg_oF7rCj8c</recordid><startdate>200610</startdate><enddate>200610</enddate><creator>IVANOVA, GABRIELA</creator><creator>ARZUMANOV, ANDREY A.</creator><creator>TURNER, JOHN J.</creator><creator>REIGADAS, SANDRINE</creator><creator>TOULMÉ, JEAN-JACQUES</creator><creator>BROWN, DOUGLAS E.</creator><creator>LEVER, ANDREW M.L.</creator><creator>GAIT, MICHAEL J.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>200610</creationdate><title>Anti-HIV Activity of Steric Block Oligonucleotides</title><author>IVANOVA, GABRIELA ; ARZUMANOV, ANDREY A. ; TURNER, JOHN J. ; REIGADAS, SANDRINE ; TOULMÉ, JEAN-JACQUES ; BROWN, DOUGLAS E. ; LEVER, ANDREW M.L. ; GAIT, MICHAEL J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-HIV Agents - administration &amp; dosage</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>antiviral</topic><topic>Cells, Cultured</topic><topic>Drug Delivery Systems - methods</topic><topic>HIV</topic><topic>HIV - genetics</topic><topic>HIV Long Terminal Repeat - drug effects</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>oligonucleotide</topic><topic>Oligonucleotides - pharmacology</topic><topic>Oligonucleotides - therapeutic use</topic><topic>Peptide Nucleic Acids - therapeutic use</topic><topic>RNA, Viral - drug effects</topic><topic>steric block</topic><topic>virucide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IVANOVA, GABRIELA</creatorcontrib><creatorcontrib>ARZUMANOV, ANDREY A.</creatorcontrib><creatorcontrib>TURNER, JOHN J.</creatorcontrib><creatorcontrib>REIGADAS, SANDRINE</creatorcontrib><creatorcontrib>TOULMÉ, JEAN-JACQUES</creatorcontrib><creatorcontrib>BROWN, DOUGLAS E.</creatorcontrib><creatorcontrib>LEVER, ANDREW M.L.</creatorcontrib><creatorcontrib>GAIT, MICHAEL J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IVANOVA, GABRIELA</au><au>ARZUMANOV, ANDREY A.</au><au>TURNER, JOHN J.</au><au>REIGADAS, SANDRINE</au><au>TOULMÉ, JEAN-JACQUES</au><au>BROWN, DOUGLAS E.</au><au>LEVER, ANDREW M.L.</au><au>GAIT, MICHAEL J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-HIV Activity of Steric Block Oligonucleotides</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>2006-10</date><risdate>2006</risdate><volume>1082</volume><issue>1</issue><spage>103</spage><epage>115</epage><pages>103-115</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><abstract>:  The unabated increase in spread of HIV infection worldwide has redoubled efforts to discover novel antiviral and virucidal agents that might be starting points for clinical development. Oligonucleotides and their analogs targeted to form complementary duplexes with highly conserved regions of the HIV RNA have shown significant antiviral activity, but to date clinical studies have been dominated by RNase H‐inducing oligonucleotide analog phosphorothioates (GEM 91 and 92) that have specificity and efficacy limitations. However, they have proven the principle that oligonucleotides can be safe anti‐HIV drugs. Newer oligonucleotide analogs are now available, which act as strong steric block agents of HIV RNA function. We describe our ongoing studies targeting the HIV‐1 trans‐activation responsive region (TAR) and the viral packaging signal (psi) with steric block oligonucleotides of varying chemistry and demonstrate their great potential for steric blocking of viral protein interactions in vitro and in cells and describe the first antiviral studies. Peptide nucleic acids (PNA) disulfide linked to cell‐penetrating peptides (CPP) have been found to have particular promise for the lipid‐free direct delivery into cultured cells and are excellent candidates for their development as antiviral and virucidal agents.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>17145931</pmid><doi>10.1196/annals.1348.033</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0077-8923
ispartof Annals of the New York Academy of Sciences, 2006-10, Vol.1082 (1), p.103-115
issn 0077-8923
1749-6632
language eng
recordid cdi_proquest_miscellaneous_20841346
source Wiley
subjects Anti-HIV Agents - administration & dosage
Anti-HIV Agents - pharmacology
antiviral
Cells, Cultured
Drug Delivery Systems - methods
HIV
HIV - genetics
HIV Long Terminal Repeat - drug effects
Human immunodeficiency virus
Human immunodeficiency virus 1
Humans
oligonucleotide
Oligonucleotides - pharmacology
Oligonucleotides - therapeutic use
Peptide Nucleic Acids - therapeutic use
RNA, Viral - drug effects
steric block
virucide
title Anti-HIV Activity of Steric Block Oligonucleotides
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A40%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-HIV%20Activity%20of%20Steric%20Block%20Oligonucleotides&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=IVANOVA,%20GABRIELA&rft.date=2006-10&rft.volume=1082&rft.issue=1&rft.spage=103&rft.epage=115&rft.pages=103-115&rft.issn=0077-8923&rft.eissn=1749-6632&rft_id=info:doi/10.1196/annals.1348.033&rft_dat=%3Cproquest_cross%3E20833211%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4803-fdc71d1c7b144af99555e706eab8686eefd52112e73f898b419c709853d52cbe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20833211&rft_id=info:pmid/17145931&rfr_iscdi=true